Surface Oncology and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s Keytruda (pembrolizumab), an anti-PD-1 therapy.
Surface Oncology, Merck to collaborate on immuno-oncology study evaluating SRF388, targeting IL-27 + Keytruda (pembrolizumab) in solid tumors
YOU MAY BE INTERESTED IN
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H. “The discretionary request calls for $6.5 billion to...
Today Dr. Roswell Park is remembered mostly as the founder of the world’s first cancer research institute, which still bears his name proudly to this day in Buffalo, NY, but his contributions to medicine extend much further.